
JUUL e-cigarettes ban on hold, but FDA still not allowing sales
Regulatory agency’s “marketing denial order” moves to court.
The U.S. Food and Drug Administration (FDA) has put on hold its
On July 5, FDA took to Twitter to
“The agency has determined that there are scientific issues unique to the JUUL application that warrant additional review,” FDA said on the official FDA Tobacco Twitter feed. “This administrative stay temporarily suspends the marketing denial order during the additional review but does not rescind it.
“All electronic nicotine delivery systems, or ENDS products, including those made by JUUL, are required by law to have FDA authorization to be legally marketed,” the FDA announcement said. “The stay and the agency’s review does not constitute authorization to market, sell, or ship JUUL products.”
Legal fight
The FDA’s June 23 announcement dealt with the JUUL device and four types of JUULpods: Virginia tobacco flavored pods at nicotine concentrations of 5% and 3% and menthol flavored pods at nicotine concentrations of 5% and 3%.
The ban made national news, drawing positive reaction from medical organizations. Last month, the American Thoracic Society described the FDA ruling as “based largely on a technical dispute over safety data, rather than JUUL’s appeal among kids,” and not based on “highly addictive levels of nicotine salts,” or long-term health effects.
The American Lung Association said stopping sales of JUUL products “is an important step in ending the youth vaping epidemic,” and the American Medical Association criticized companies peddling e-cigarettes to youths, creating a new generation hooked on tobacco products.
The FDA announcement prompted an online rebuttal from JUUL Chief Regulatory Officer Joe Murillo. He pledged the company would seek a legal stay of the FDA order, and the company did a day later.
On June 24, FDA announced the U.S. Court of Appeals for the D.C. Circuit entered a temporary administrative stay of the marketing denial order for Juul Labs Inc.
“The court notes the purpose of this administrative stay is to give the court sufficient opportunity to consider petitioner’s forthcoming emergency motion for stay pending court review and should not be construed in any way as a ruling on the merits of that motion,” FDA said in a statement posted on Twitter.
Tobacco policy
The ruling about JUUL products marked the third significant FDA action on cigarettes, tobacco or electronic nicotine delivery systems in recent months.
On June 21, the White House published plans for future regulatory actions with FDA plans to establish a maximum nicotine level to reduce the addictiveness of cigarettes.
In April, FDA proposed
The agency will accept
Newsletter
Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.




















